PHASE-II STUDY OF DOXIFLURIDINE IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

被引：25

作者：

ABELE, R

KAPLAN, E

GROSSENBACHER, R

SCHMID, HJ

CAVALLI, F

机构：

[1] UNIV HOSP GENEVA, DIV ONCOL, CH-1211 GENEVA 4, SWITZERLAND

[2] HOSP SAN GIOVANNI, SERV ONCOL, BELLINZONA, SWITZERLAND

[3] UNIV HOSP ZURICH, EAR NOSE & THROAT CLIN, CH-8091 ZURICH, SWITZERLAND

[4] KANTONSSPITAL, CH-6004 LUCERNE, SWITZERLAND

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1984年 / 20卷 / 03期

关键词：

D O I：

10.1016/0277-5379(84)90078-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A phase II trial was conducted with 5''-deoxy-5-fluorouridine (doxifluridine) in advanced squamous cell carcinoma of the head and neck. The drug was given at the dose of 4 g/m2 daily x 5 every 3 wk. Of 20 eligible patients who entered this trial, 12 were evaluable for response to doxifluridine. The majority of these patients received previous treatment for cancer. One complete and 2 partial remissions were observed (25%). Drug-induced toxicity consisted mainly of myelosuppression, mild nausea and vomiting, stomatitis and CNS side-effects. Other dosages or schedules for doxifluridine administration might be explored in poor-risk patients.

引用

页码：333 / 336

页数：4